Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 6/20 | 0.51 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | FABP7 | O15540 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL274968 | 1.00 | GPBAR1 (0.51) | GPBAR1DDB1CRBNBRD4CREBBP | |
| SCHEMBL8777371 | 0.87 | KMT2A (0.48) | GPBAR1BRD4CREBBPNPC1RAB9A | |
| SCHEMBL24818238 | 0.86 | CRBN (0.53) | GPBAR1DDB1CRBNTSHRGAA | |
| SCHEMBL2245383 | 0.85 | LMNA (0.55) | GPBAR1GAASMN1; SMN2 | |
| SCHEMBL5552455 | 0.81 | MMP1 (0.46) | GPBAR1GLANPC1RAB9A | |
| SCHEMBL24125403 | 0.79 | ALDH1A1 (0.44) | GPBAR1DDB1CRBNGLATSHR | |
| SCHEMBL7369383 | 0.77 | TSHR (0.49) | GPBAR1DDB1CRBNBRD4CREBBP | |
| SCHEMBL148443 | 0.77 | GPBAR1 (0.46) | GPBAR1DDB1CRBNBRD4CREBBP | |
| SCHEMBL27280429 | 0.77 | TSHR (0.49) | GPBAR1DDB1CRBNBRD4CREBBP | |
| SCHEMBL29088638 | 0.77 | ALDH1A1 (0.46) | DDB1CRBNTSHRRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070111928-A1 | Didemnin analogs and fragments and methods of making and using them | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2007-05-17 | — | — | US | disclosed |
| EP-1276491-B9 | TAMANDARIN AND DIDEMNIN ANALOGS AND METHODS OF MAKING AND USING THEM | UNIV PENNSYLVANIA (US) | 2007-02-28 | — | — | EP | disclosed |
| US-7122519-B2 | Didemnin analogs and fragments and methods of making and using them | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1276491-B1 | TAMANDARIN AND DIDEMNIN ANALOGS AND METHODS OF MAKING AND USING THEM | UNIV PENNSYLVANIA (US) | 2006-09-20 | — | — | EP | disclosed |
| EP-1276491-A4 | TAMANDARIN AND DIDEMNIN ANALOGS AND METHODS OF MAKING AND USING THEM | UNIV PENNSYLVANIA (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20030104991-A1 | Didemnin analogs and fragments and methods of making and using them | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2003-06-05 | — | — | US | disclosed |
| EP-1276491-A1 | TAMANDARIN AND DIDEMNIN ANALOGS AND METHODS OF MAKING AND USING THEM | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2003-01-22 | — | — | EP | disclosed |
| US-6509315-B1 | Useful for, among other things, inhibiting protein synthesis, cell growth, cell proliferation, and tumorigenesis | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2003-01-21 | — | — | US | disclosed |
| WO-2001076616-A1 | TAMANDARIN AND DIDEMNIN ANALOGS AND METHODS OF MAKING AND USING THEM | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030104991-A1 | Didemnin analogs and fragments and methods of making and using them | BAD, MDN1, HDGF | GPBAR1 4797/4885DDB1 89/4885CRBN 725/4885 |
| US-20070111928-A1 | Didemnin analogs and fragments and methods of making and using them | BAD, MDN1, HDGF | GPBAR1 4797/4885DDB1 89/4885CRBN 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.